POETYK SLE-2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)
Principal Investigator(s): Arik Zaider, MD
Status: Open and enrolling